3billion, Inc.
KKRX:3948005,000.00
KRW
-270.00
(-5.12%)
ISIN
KR7394800007
Return %
Stock
S&P 500
1Y
-39.47
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Chang-Won Geum
- Full Time Employees
- 98
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Seoul South Korea
- IPO Date
- Nov 14, 2024
- Website
- 3billion.io
- Similar Companies
- Business
- 3billion, Inc. is a South Korea-based biotechnology and precision medicine company that develops and provides artificial intelligence-powered genetic testing, variant interpretation software, and genomic drug discovery solutions for rare genetic diseases. The company operates through two primary business segments: Diagnostic Genomic Services and AI Software and Drug Discovery Platforms. Its clinical diagnostics portfolio includes comprehensive genomic testing services, such as 3B-EXOME, a whole exome sequencing test that analyzes protein-coding regions for diagnostic variants; 3B-GENOME, a clinical-grade whole genome sequencing test providing full genomic coverage including non-coding and structural variants; 3B-NEO, a newborn genetic screening panel designed for the early detection of treatable inherited disorders; and targeted gene panel sequencing tailored to specific clinical phenotypes and hereditary disorders. The company also offers proprietary software platforms, including EVIDENCE, an automated clinical-grade variant interpretation system capable of analyzing patient symptoms and genomic variants against thousands of rare disease profiles; 3Cnet, a deep learning-based pathogenicity predictor for genetic variants; and GEBRA, a cloud-based genomic variant re-analysis and interpretation software-as-a-service platform for hospitals, geneticists, and clinical research laboratories. In addition, the company leverages its genomic database to provide AI-driven target identification and drug discovery services through its MIN-T platform, assisting biopharmaceutical partners in identifying novel therapeutic targets and validating drug candidates for rare conditions. 3billion, Inc. serves hospitals, clinical laboratories, academic medical centers, and biopharmaceutical enterprises across more than 60 countries worldwide, with diagnostic facilities holding College of American Pathologists accreditation and Clinical Laboratory Improvement Amendments certification. In recent developments, 3billion completed its initial public offering on the KOSDAQ market under the ticker symbol 394800 in November 2024. The company has expanded its international operations by establishing a United States presence in Austin, Texas, and entering into a strategic commercial collaboration with Psomagen to accelerate clinical genomics adoption in North America. Furthermore, the company has entered into a diagnostic collaboration with AstraZeneca Korea to advance AI-based genetic screening for atypical hemolytic uremic syndrome and partnered with Kazakhstan's Center for Molecular Medicine to establish a regional genomic diagnostics hub across Central Asia. Founded in 2016, 3billion, Inc. is headquartered in Seoul, South Korea.